Innovative Diagnostic Products Transplant Genomics has developed cutting-edge non-invasive blood-based gene expression tests like TruGraf Liver and OmniGraf, providing valuable solutions for organ rejection monitoring and immunosuppression management, which could be expanded to other transplant or diagnostic markets.

Recent Product Launches The company’s recent launches of TruGraf Liver and OmniGraf demonstrate a strong pipeline and commitment to advancing transplant diagnostics, presenting opportunities to collaborate on additional tests or expand existing offerings to broader transplantation procedures.

Market Recognition Receiving the Medical Innovation Award from the National Kidney Foundation highlights the company’s reputation for scientific excellence and innovation, fostering potential partnerships with healthcare providers and advocacy groups looking for validated, innovative solutions.

Strategic Acquisition Being acquired by Eurofins Scientific in 2019 has enhanced Transplant Genomics’ resources and reach, creating opportunities for joint ventures with Eurofins’ extensive laboratory network and expanding into new geographic or clinical markets.

Growing Industry Presence As a focused biotech with a specialized niche in transplant diagnostics, Transplant Genomics can leverage its technological expertise and recent product success to attract ongoing investments, research collaborations, and customer relationships within the expanding personalized medicine and transplant markets.